Navigation Links
MINRAD International, Inc. Announces Reduction in Workforce
Date:11/20/2008

ort the transfer of these procedures to the outpatient setting. The Company is in the process of developing a drug /drug delivery system for the use of halogenated ethers as inhalation analgesics for conscious sedation.

Forward-Looking Statements

The information contained in this news release, other than historical information, consists of forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may involve risks and uncertainties that could cause actual results to differ materially from those described in such statements. Factors that may cause actual results to differ materially from those expressed or implied by its forward-looking statements include, but are not limited to, MINRAD International's limited operating history and business development associated with being a growth stage company; its dependence on key personnel; its need to attract and retain technical and managerial personnel; its ability to execute its business strategy; the intense competition it faces; its ability to protect its intellectual property and proprietary technologies; its exposure to product liability claims resulting from the use of its products; general economic and capital market conditions; financial conditions of its customers and their perception of its financial condition relative to that of its competitors; as well as those risks described under the heading "Risk Factors" of MINRAD International's Form 10-KSB/A, filed with the Securities and Exchange Commission on April 21, 2008. Although MINRAD International, Inc. believes that the expectations reflected in such forward-looking statements are reasonable, it can give no assurance that such expectations will prove to have been correct.


'/>"/>
SOURCE MINRAD International, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. MINRAD International, Inc. to Discuss 2008 First Quarter Financial Results on Tuesday, May 13, 2008
2. MINRAD International, Inc. Announces $40.0 Million Private Placement
3. MINRAD International, Inc. Announces Appointment of David T. DiGiacinto as President and Chief Operating Officer
4. Medizone International, Inc. Announces Establishment of Canadian Foundation for Global Health
5. Sangui Biotech International, Inc., Reports Sales Decrease, Continued Losses
6. Cryo-Cell International, Inc. Reports Third Quarter 2008 Results
7. China Yingxia International, Inc. Announces $2 Million Share Repurchase Program
8. BioEnergy International, LLC Announces Norman R. Augustine to Join Advisory Board
9. China Yingxia International, Inc. Appoints New Vice President of Finance
10. Chindex International, Inc. Announces Appearances at Upcoming Investor Conferences
11. Sangui BioTech International, Inc. Files Remaining Reports
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/3/2009)... (Nasdaq: VIAP ), a biotechnology company focused on ... and metabolic disease, today announced that it has completed ... clinical trial of VIA-2291. ,, The FDG-PET trial ... sites in the US and Canada including Massachusetts General ...
(Date:12/3/2009)... Medical Innovations, Inc. (NYSE: IMA ), a global ... at home through the merger of rapid diagnostics and health ... its Series B Convertible Perpetual Preferred Stock ( IMA-PB). The ... in an amount per share equal to the quotient of ...
(Date:12/2/2009)... Dec. 2 Martek Biosciences Corporation (Nasdaq: MATK ) ... its fourth quarter and fiscal year 2009 on December 16, ... the release, at 4:45 p.m. ET Martek will conduct a ... interested parties may listen to the call live via webcast ...
(Date:12/2/2009)... announces that a new market research report ... Carbondioxide Incubators - A Global Market Perspective ... Incubators are the most critical equipment used ... applications for providing a controlled environment to ...
Breaking Biology Technology:VIA Pharmaceuticals Completes Patient Visits in Phase 2 Trial of VIA-2291 2VIA Pharmaceuticals Completes Patient Visits in Phase 2 Trial of VIA-2291 3VIA Pharmaceuticals Completes Patient Visits in Phase 2 Trial of VIA-2291 4Martek to Announce Fourth Quarter and Fiscal Year 2009 Results 2Reportlinker Adds Carbondioxide Incubators - A Global Market Perspective 2Reportlinker Adds Carbondioxide Incubators - A Global Market Perspective 3Reportlinker Adds Carbondioxide Incubators - A Global Market Perspective 4
... Jan. 31 China Agro-Technology,Holdings Ltd ("CAT") today announced ... Chief Executive Officer, replacing interim CEO Harry,He, effective as ... New York., CAT is a leading agro-biotechnology company ... The company reported total audited revenues of,US$37 million in ...
... 31 /PRNewswire-FirstCall/ - MIGENIX Inc.,(TSX: MGI, OTC: MGIFF), ... add a 600mg celgosivir combination therapy arm to ... hepatitis C virus,("HCV") treatment-naive patients. The protocol amendment ... Review Board (IRB) approvals. The,purpose of this new ...
... and Therapies ... for Paralysis, ... (CDRF), which is dedicated to curing spinal cord injury by,funding innovative ... through grants, information and advocacy, today,announced it has awarded $1,996,745 million ...
Other Biology Technology:China Agro-Technology Appoints New CEO 2China Agro-Technology Appoints New CEO 3MIGENIX to Add 600mg Daily Celgosivir Dose to Phase II Viral Kinetics Study 2MIGENIX to Add 600mg Daily Celgosivir Dose to Phase II Viral Kinetics Study 3MIGENIX to Add 600mg Daily Celgosivir Dose to Phase II Viral Kinetics Study 4MIGENIX to Add 600mg Daily Celgosivir Dose to Phase II Viral Kinetics Study 5MIGENIX to Add 600mg Daily Celgosivir Dose to Phase II Viral Kinetics Study 6Christopher and Dana Reeve Foundation Awards Nearly $2 Million in Individual Research Grants 2Christopher and Dana Reeve Foundation Awards Nearly $2 Million in Individual Research Grants 3
(Date:12/3/2009)... Antarctic snowmelt that occurred during the 2008-09 austral summer ... two main climate drivers, ENSO (El Nio - Southern ... Dr. Marco Tedesco, Assistant Professor of Earth & Atmospheric ... , Professor Tedesco, who is also on the ...
(Date:12/2/2009)... PHILADELPHIA Cigarette smoking and alcohol consumption before head ... risk of death, according to published studies. Now, results ... those who continued these habits after cancer diagnosis. , ... this, many still smoke. In our study, 21 percent ...
(Date:12/2/2009)... did not prompt people participating in a long-term ... up their cigarettes again, researchers wrote in a ... Prevention , a journal of the American Association ... special focus on tobacco. , These findings should ...
Breaking Biology News(10 mins):CCNY professor foresees rising Antarctic snowmelt 2Head and neck cancer survivors who use alcohol and cigarettes have increased death risk 2Repeat negative CT scan for lung cancer does not encourage ex-smokers to resume the habit 2Ophthalmologists Invited To Participate in Betadine for EKC Treatment Study 50686 1Ophthalmologists Invited To Participate in Betadine for EKC Treatment Study 50686 2Odd Behaviors on Ambien Linked to Brain Circuitry 50681 1Odd Behaviors on Ambien Linked to Brain Circuitry 50681 2ACT Announces Partnership With Gilead Sciences Inc 12883 1
... A team of scientists employing a sophisticated computer model ... has found that many governments worldwide are recommending the ... of many drugs and therapies to treat malaria, many ... a single first-line therapy -- that is, using one ...
... is shown via a sequence of satellite images acquired ... 25 August, 28 August, 30 August and 1 September ... 25 August 2008 some 400 km southeast of Port-au-Prince, ... wave developed curved bands and an upper level eye ...
... gene, in different ways, so it comes as little surprise that ... a gene, according to a new study appearing in the October ... that gene, is based on the analysis of 300 articles in ... Mail from the UK; and Aftenposten, Dagbladet, and VG from Norway. ...
Other Biology News:Best way to treat malaria: Avoid using same drug for everyone, scientists say 2Best way to treat malaria: Avoid using same drug for everyone, scientists say 3Hurricane Gustav 2What is a gene? 2
... The M-840 HEXALIGHT robot is based on ... (PKM) over more than a decade. PI ... for mirror and antenna adjustments over wide ... provides six degrees of freedom with 3 ...
... DNA sequencing is the experimental process of ... region. The automated DNA Sequencing is based ... DNA polymerase, which allows cycle sequencing reactions. ... detected in a capillary instrument controlled by ...
...
High-throughput DNA sequencing of any library. Just give us your transformation mixture, and we'll do the rest. ABI 3730xl's yield the longest read lengths available. LIMS tracking utilizing Geospiza...
Biology Products: